Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply
- PMID: 34973222
- DOI: 10.1016/S1470-2045(21)00712-9
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply
Conflict of interest statement
CY received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Celgene, Bristol Myers Squibb, Debiopharm, Ipsen, Kyowa Kirin, Novartis, Boryung Pharmaceuticals, Merck Serono, Mundipharma, Roche, and Janssen; and received research grants from Servier, Bayer, AstraZeneca, Ono Pharmaceuticals, Celgene, Ipsen, Boryung Pharmaceuticals, Ildong Pharmaceuticals, CKD Pharmaceuticals, and HK inno.N.
Comment in
-
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.Lancet Oncol. 2022 Jan;23(1):e11. doi: 10.1016/S1470-2045(21)00664-1. Lancet Oncol. 2022. PMID: 34973221 No abstract available.
Dataset described in
-
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656226 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources